Jamie Nicole LaBuzetta1, Albert J Yoo2, Syed Ali2, Kaitlin Fitzpatrick1, Thabele Leslie-Mazwi3, Joshua A Hirsch2, Lee Schwamm1, Natalia Rost4. 1. Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts. 2. Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts. 3. Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts; Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts. 4. Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: nrost@partners.org.
Abstract
BACKGROUND: Proximal artery occlusions (PAO) recanalize in only a small percentage of acute ischemic stroke (AIS) patients treated with intravenous tissue plasminogen activator (IV tPA) alone, yet the benefits of adjunctive or substitutive intra-arterial therapy (IAT) in this patient subgroup are not well established. We evaluated early poststroke outcomes in a cohort of AIS patients with PAO categorized as "likely to benefit" (LTB) from IAT using prespecified criteria. METHODS: Using a prespecified protocol, 193 patients from our institutional stroke database admitted between January 1, 2007, and December 31, 2011, were prospectively deemed LTB from IAT. Logistic regression was used to determine independent predictors of favorable (discharge to home or acute rehabilitation) versus unfavorable (discharge to skilled nursing facility, hospice, or in-hospital mortality) outcome. RESULTS: Of the patients included, 29.5% received IV tPA only, 11.4% underwent IAT only, and 37.8% had both. Overall in-hospital mortality was 19.2%. In a univariate analysis, age (odds ratio [OR], .95; 95% confidence interval [CI], .93-.98), IV tPA (OR, 2.3; 95% CI, 1.2-4.3), and history of atrial fibrillation (OR, .5; 95% CI, .28-.97) were associated with outcome. Effect of IAT was not statistically significant (OR, 1.3; 95% CI, .7-2.3; P = .4). In multivariate analysis, the only independent predictor of favorable outcome was IV tPA administration (OR, 2.4; 95% CI, 1.2-5.0). The odds of favorable poststroke outcome were significantly lowered (OR, .3; 95% CI, .1-.6; P = .0006) in those receiving neither IV tPA nor IAT. CONCLUSIONS: In AIS patients with PAO thought most likely to benefit from IAT, IV tPA independently predicted favorable outcomes. These data reinforce the recommendation to provide early IV tPA to all eligible patients.
BACKGROUND: Proximal artery occlusions (PAO) recanalize in only a small percentage of acute ischemic stroke (AIS) patients treated with intravenous tissue plasminogen activator (IV tPA) alone, yet the benefits of adjunctive or substitutive intra-arterial therapy (IAT) in this patient subgroup are not well established. We evaluated early poststroke outcomes in a cohort of AISpatients with PAO categorized as "likely to benefit" (LTB) from IAT using prespecified criteria. METHODS: Using a prespecified protocol, 193 patients from our institutional stroke database admitted between January 1, 2007, and December 31, 2011, were prospectively deemed LTB from IAT. Logistic regression was used to determine independent predictors of favorable (discharge to home or acute rehabilitation) versus unfavorable (discharge to skilled nursing facility, hospice, or in-hospital mortality) outcome. RESULTS: Of the patients included, 29.5% received IV tPA only, 11.4% underwent IAT only, and 37.8% had both. Overall in-hospital mortality was 19.2%. In a univariate analysis, age (odds ratio [OR], .95; 95% confidence interval [CI], .93-.98), IV tPA (OR, 2.3; 95% CI, 1.2-4.3), and history of atrial fibrillation (OR, .5; 95% CI, .28-.97) were associated with outcome. Effect of IAT was not statistically significant (OR, 1.3; 95% CI, .7-2.3; P = .4). In multivariate analysis, the only independent predictor of favorable outcome was IV tPA administration (OR, 2.4; 95% CI, 1.2-5.0). The odds of favorable poststroke outcome were significantly lowered (OR, .3; 95% CI, .1-.6; P = .0006) in those receiving neither IV tPA nor IAT. CONCLUSIONS: In AISpatients with PAO thought most likely to benefit from IAT, IV tPA independently predicted favorable outcomes. These data reinforce the recommendation to provide early IV tPA to all eligible patients.
Authors: T A Tomsick; P Khatri; T Jovin; B Demaerschalk; T Malisch; A Demchuk; M D Hill; E Jauch; J Spilker; J P Broderick Journal: Neurology Date: 2010-03-30 Impact factor: 9.910
Authors: Albert J Yoo; Elizabeth R Barak; William A Copen; Shahmir Kamalian; Leila Rezai Gharai; Muhammad A Pervez; Lee H Schwamm; R Gilberto González; Pamela W Schaefer Journal: Stroke Date: 2010-07-01 Impact factor: 7.914
Authors: Maher Saqqur; Ken Uchino; Andrew M Demchuk; Carlos A Molina; Zsolt Garami; Sergio Calleja; Naveed Akhtar; Finton O Orouk; Abdul Salam; Ashfaq Shuaib; Andrei V Alexandrov Journal: Stroke Date: 2007-02-08 Impact factor: 7.914
Authors: Ronil V Chandra; Thabele M Leslie-Mazwi; Daniel C Oh; Zeshan A Chaudhry; Brijesh P Mehta; Natalia S Rost; James D Rabinov; Joshua A Hirsch; R Gilberto González; Lee H Schwamm; Albert J Yoo Journal: Stroke Date: 2012-06-28 Impact factor: 7.914
Authors: Parham Moftakhar; Joey D English; Daniel L Cooke; Warren T Kim; Charles Stout; Wade S Smith; Christopher F Dowd; Randall T Higashida; Van V Halbach; Steven W Hetts Journal: Stroke Date: 2012-10-30 Impact factor: 7.914
Authors: Peter Sandercock; Joanna M Wardlaw; Richard I Lindley; Martin Dennis; Geoff Cohen; Gordon Murray; Karen Innes; Graham Venables; Anna Czlonkowska; Adam Kobayashi; Stefano Ricci; Veronica Murray; Eivind Berge; Karsten Bruins Slot; Graeme J Hankey; Manuel Correia; Andre Peeters; Karl Matz; Phillippe Lyrer; Gord Gubitz; Stephen J Phillips; Antonio Arauz Journal: Lancet Date: 2012-05-23 Impact factor: 79.321
Authors: Hasan H Karadeli; Dan-Victor Giurgiutiu; Lisa Cloonan; Kaitlin Fitzpatrick; Allison Kanakis; Muhammed E Ozcan; Lee H Schwamm; Natalia S Rost Journal: J Neuroimaging Date: 2015-08-06 Impact factor: 2.486